Omnicell Stock Analysis, Valuation (NASDAQ:OMCL)

Add to My Stocks
$42.15 $0.05 (0.12%) OMCL stock closing price Mar 23, 2018 (Closing)
Watch Robo Advisor Video of OMCL Stock Analysis
Updated on : Mar 23, 2018
previous close
OMCL 42.2 (0%)
S&P 500 2588.3 (0%)
Closing Price On: Mar 23, 2018
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Information Systems
Sector :
5 Quarter Revenue
Revenue Growth
Compared to the industry
Operating Profit
Operating Margin:
Sector Average:
5 Quarter Net Profit
Net Margins
LTM Margin
Compared to the industry
Debt/Equity Ratio
Debt/Equity Ratio:
Compared to the industry
Cash Flow
Operating cash flow:
Net Income:
Recent Growth
Net Margins
PS Valuation
High Debt Burden
Cash Flow
FCF Margin
PE Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
Industry PS :
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
Return on Equity:
Free Cash Flow Margin:
Double Tap To Exit Full Screen

Omnicell Stock Analysis

71 6 2

Investors can watch the Amigobulls Omnicell stock analysis video here. Our analyst opinion covering the buy and sell arguments for OMCL stock is shown in the video.

Note: Amigobulls stock rating is our opinion based on the historical performance of the company's fundamentals. It is not indicative of the future performance of the stock.

Omnicell, Inc. Stock Rating 3.1/5

Amigobulls OMCL stock analysis relies on business fundamentals such as Omnicell revenue growth, profits and return on equity measures from the latest quarter 2017 Q4 earnings. Omnicell valuation forms a crucial part of our stock analysis. Based on a company's historical fundamentals we arrive at Omnicell stock rating which is indicative of the company's financial performance.

Should you buy OMCL stock?

  • Omnicell's revenue growth came in at 15.1% in 2017 Q4.
  • Net margins came in at average 2.9% for Omnicell over the last twelve months.
  • The lower PS ratio 2.2 for OMCL stock versus Medical-Information Systems industry average of 5.6 is a positive for the company.
  • Omnicell has a good Return On Equity (ROE) of 4.5%.

Should you sell OMCL stock?

  • With a debt/equity ratio of  0.41, Omnicell is highly leveraged in comparison to Medical peers.
  • Cash flow from operations is low at 0.2 times the net income.
  • The OMCL stock currently trades at a PE of 247.9, which is expensive, compared to the industry average of 23.2.
  • Omnicell's negative ROIC of -20.9% indicates operational inefficiency.
  • The company has negative Free Cash Flows (FCF), with a negative FCF margin of -3.4%.

Comments on this video and Omnicell stock

Amigobulls Omnicell stock analysis helps in evaluating the financial statements of a company to arrive at a conclusion about the fair value of OMCL stock. Company's fundamentals remain one of the key driver of OMCL stock and helps investors in making good buy and sell decision.

Omnicell revenue growth and profit or net income are the main underlying forces which could detremine the direction of the share price. One can also combine technical analysis and fundamental analysis to get a holistic picture about OMCL stock.